Long‐Term Outcomes Among Lung Transplant Recipients With High‐Risk Cytomegalovirus Mismatch Managed With a Multimodality Regimen
Open Access
- 30 June 2025
- journal article
- Published by Wiley in Clinical Transplantation
- Vol. 39 (7) , e70219
Abstract
Background: Lung transplant (LT) recipients with high‐risk cytomegalovirus (CMV) mismatch donors (donor seropositive, recipient seronegative) have worse early and late outcomes. We sought to describe the outcomes among high‐risk mismatch patients managed using proactive monitoring and multimodality prophylaxis and management protocol.Methods: We included patients with single or bilateral lung transplants between January 2012 and December 2016 (n = 324). The patients were classified into two groups: high‐risk CMV mismatch (R−/D+): n = 83 (25.6%) and non‐high‐risk CMV mismatch (n = 241). Post‐LT follow‐up period ranged from 8 to 12 years. Post‐transplant survival was analyzed as the primary outcome variable.Results: There was no difference in LT recipients' baseline and post‐transplant characteristics with and without CMV‐mismatch donors. The mismatch group experienced a significantly higher frequency and burden of CMV viremia (p < 0.001) and resistant viremia (p < 0.001). Regardless, the two groups had similar long‐term outcomes with no statistically significant difference in CLAD‐free survival at 3 years or overall post‐transplant survival. On Cox proportional hazard analysis, transplant indication was the only independent predictor of post‐transplant survival (p = 0.004).Conclusions: A proactive multimodality CMV management protocol consisting of antiviral agents (ganciclovir/valganciclovir) and immune augmentation with CMV immune globulin may improve outcomes among high‐risk CMV mismatch LT recipients.Keywords
This publication has 34 references indexed in Scilit:
- Cytomegalovirus and Lung TransplantationAmerican Journal of Transplantation, 2004
- Acute renal failure – definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) GroupCritical Care, 2004
- Delay of CMV infection in high‐risk CMV mismatch lung transplant recipients due to prophylaxis with oral ganciclovirClinical Transplantation, 2004
- Combination Prophylaxis with Ganciclovir and Cytomegalovirus (CMV) Immune Globulin After Lung Transplantation: Effective CMV Prevention Following Daclizumab InductionAmerican Journal of Transplantation, 2003
- Cytomegalovirus (CMV) resistance to antivirals.2001
- IMPACT OF CYTOMEGALOVIRUS HYPERIMMUNE GLOBULIN ON OUTCOME AFTER CARDIOTHORACIC TRANSPLANTATIONTransplantation, 2001
- Intravenous ganciclovir prophylaxis for cytomegalovirus in heart, heart-lung, and lung transplant recipientsTransplant International, 1999
- Cytomegalovirus Immune Globulin Prophylaxis in Liver TransplantationAnnals of Internal Medicine, 1993
- Lungs are a major organ site of cytomegalovirus latency and recurrenceJournal of Virology, 1993
- Use of Cytomegalovirus Immune Globulin to Prevent Cytomegalovirus Disease in Renal-Transplant RecipientsNew England Journal of Medicine, 1987